AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

863.185

-8.198-0.94%

Number of Gainers:12

Number of Losers:18

Number of Flat:16

PE:- -

High:871.441

Open:871.383

Low:858.404

Close:871.383

Loading ...

BlackRock to reassess Australian exposure amid stretched valuations, weak growth

BUZZ-Australia's Monash IVF Group rises on upbeat results, forecast

Mesoblast Sets Ryoncil Drug Price Ahead of Product Launch

MT Newswires Live

Imugene Receives Patent for Oncolytic Virotherapy Technology in India; Shares Rise 3%

MT Newswires Live

BRIEF-Respiri Seeks Trading Halt Pending Announcement Regarding A Capital Raising

BRIEF-Imugene Granted India Patent For Oncolytic Virotherapy CF33

BRIEF-Monash IVF Group Sees FY2025 Underlying Group NPAT Between A$30.0M And A$31.0M

BRIEF-Mesoblast Says HY Loss Attributable $47.9 Million

BRIEF-Imricor Medical Systems Says Net Loss For Year A$29.7 Million

BRIEF-CSL Says Swissmedic Approves Andembry To Prevent Recurrent Attacks Of Hereditary Angioedema

Clinuvel Pharmaceuticals Ltd H1 Net Income AUD 14.08 Million

THOMSON REUTERS

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

THOMSON REUTERS

Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Respiri Ltd - Seeks Trading Halt Pending Announcement Regarding a Capital Raising

THOMSON REUTERS

Monash IVF Group Ltd - FY2025 Underlying Group Npat Expected to Be Between a$30.0M and a$31.0M

THOMSON REUTERS

Monash IVF Group H1 Adjusted Ebitda AUD 35.592 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":863.1849,"timestamp":1741237199889,"preClose":871.38275,"halted":0,"volume":66121544,"delay":0,"changeRate":-0.009408,"change":-8.197876,"amount":173611356,"amplitude":0.014961,"prevYearClose":936.801,"fiveDayClose":865.483,"twentyDayClose":911.777,"turnoverRate":0.001788,"marketCap":138819092578.25,"floatMarketCap":135471653394.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":871.4405,"amplitude":0.014961,"preClose":871.38275,"low":858.4041,"latestPrice":863.1849,"volume":66121544,"delay":0,"open":871.3828,"prevYearClose":936.801,"prevWeekClose":863.841,"prevMonthClose":863.841,"prevQuarterClose":936.801,"fiveDayClose":865.483,"twentyDayClose":911.777,"sixtyDayClose":930.491,"secType":"PLATE","market":"AU","turnoverRate":0.001788,"marketCap":138819092578.25,"floatMarketCap":135471653394.25,"timestamp":1741237199889,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":18,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:16,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514103338","title":"BlackRock to reassess Australian exposure amid stretched valuations, weak growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2514103338","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514103338?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:29","pubTimestamp":1740626993,"startTime":"0","endTime":"0","summary":"that 4% unemployment rate obviously is causing them a bit of consternation,\" said Craig Vardy, BlackRock's Australasia head of fixed income.That would reduce the prospect for more rate cuts to stimulate growth for Australia's households, he added.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI06Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","BHP.AU","BK4135","BK7501","LU1509826696.USD","LU1670628061.USD","LU2430703095.HKD","BK4534","LU0980610538.SGD","BK4535","LU2264538146.SGD","IE00B64PRP62.GBP","IE00B3PB1722.GBP","LU1074936037.SGD","LU1291159041.SGD","LU1201861249.SGD","BLK","BK4533","LU0731783048.USD","BK7507","IE00BVYPNV92.GBP","BK4581","LU0772969993.USD","BK4567","LU2592432038.USD","LU0320765489.SGD","LU0731783394.SGD","CSL.AU","IE00BVYPNW00.USD","LU0640476718.USD","BK7067","IE00BGHQF631.EUR","LU1670627923.USD","LU1280957306.USD","IE00BDGV0183.EUR","LU2505996509.AUD","LU2430703178.SGD","LU0208291251.USD","LU1481011911.USD","BK7135","BK4504","BK4588","LU0742537680.HKD","BK7511","LU1599440770.SGD","CBA.AU","IE00BGHQF748.EUR","LU1481011671.HKD","BK7508","BK7095"],"gpt_icon":1},{"id":"2514503817","title":"BUZZ-Australia's Monash IVF Group rises on upbeat results, forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2514503817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514503817?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:11","pubTimestamp":1740625911,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Monash IVF Group rises on upbeat results, forecast** Shares of Monash IVF Group MVF.AX rise 4.7% to A$1.22** Stock hits highest level since mid-January** The fertility services provider posts 1H25 underlying NPAT of A$15.8 million, up 5.5% from previous year** Co expects to record underlying group NPAT between A$30 million and A$31 million in FY25 compared to A$29.9 million in FY24** Co posts 1H25 revenue growth of 11.6% to A$10.3 million ** About 810,200 shares change hands, 1.3 times the 30-day average volume of shares** Stock down 8.3% this year, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL3N3PI07Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MVF.AU","BK7113","BK7508"],"gpt_icon":0},{"id":"2514175618","title":"Mesoblast Sets Ryoncil Drug Price Ahead of Product Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2514175618","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514175618?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:09","pubTimestamp":1740625788,"startTime":"0","endTime":"0","summary":"Mesoblast  set the price for its Ryoncil mesenchymal stromal cell therapy as it seeks to launch the product in the coming weeks, according to a Thursday Australian bourse filing.Ryoncil is a mesenchymal stromal cell therapy approved by the US Food and Drug Administration on Dec. 18, 2024, as the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease.The firm said its commercial execution is underway, and it is engaging with the top 45 centers representing 80% of pediatric transplants in the US.Mesoblast plans to further evaluate the immunomodulatory effects of Ryoncil on gastrointestinal inflammation in treating medically refractory pediatric Crohn's disease patients.The company's shares rose past 2% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7501","BK7067","MESO","MSB.AU","BK7508"],"gpt_icon":1},{"id":"2514814255","title":"Imugene Receives Patent for Oncolytic Virotherapy Technology in India; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514814255","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514814255?lang=en_us&edition=fundamental","pubTime":"2025-02-27 10:41","pubTimestamp":1740624075,"startTime":"0","endTime":"0","summary":"Imugene  obtained a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology, according to a Thursday filing with the Australian bourse.The patent is set to expire in 2037. The technology already has intellectual property protection in the US and Japan, the filing said.The clinical-stage immuno-oncology company's shares rose 3% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2514815737","title":"BRIEF-Respiri Seeks Trading Halt Pending Announcement Regarding A Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2514815737","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514815737?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:36","pubTimestamp":1740620196,"startTime":"0","endTime":"0","summary":"BRIEF-Respiri Seeks Trading Halt Pending Announcement Regarding A Capital RaisingFeb 27 (Reuters) - Respiri Ltd RSH.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT REGARDING A CAPITAL RAISINGFurther company coverage: RSH.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1L2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","RSH.AU","BK7508","BK7503"],"gpt_icon":0},{"id":"2514815226","title":"BRIEF-Imugene Granted India Patent For Oncolytic Virotherapy CF33","url":"https://stock-news.laohu8.com/highlight/detail?id=2514815226","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514815226?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:35","pubTimestamp":1740620134,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Granted India Patent For Oncolytic Virotherapy CF33Feb 27 (Reuters) - Imugene Ltd IMU.AX:IMUGENE GRANTED INDIA PATENT FOR ONCOLYTIC VIROTHERAPY CF33Further company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2514154368","title":"BRIEF-Monash IVF Group Sees FY2025 Underlying Group NPAT Between A$30.0M And A$31.0M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514154368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514154368?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:33","pubTimestamp":1740620008,"startTime":"0","endTime":"0","summary":"BRIEF-Monash IVF Group Sees FY2025 Underlying Group NPAT Between A$30.0M And A$31.0MFeb 27 (Reuters) - Monash IVF Group Ltd MVF.AX:FY2025 UNDERLYING GROUP NPAT EXPECTED TO BE BETWEEN A$30.0M AND A$31.0MFurther company coverage: MVF.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MVF.AU","BK7113"],"gpt_icon":0},{"id":"2514057813","title":"BRIEF-Mesoblast Says HY Loss Attributable $47.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514057813","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514057813?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:17","pubTimestamp":1740619049,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says HY Loss Attributable $47.9 MillionFeb 27 (Reuters) - Mesoblast Ltd MSB.AX:HY LOSS ATTRIBUTABLE $47.9 MILLIONHY REVENUE $3.2 MILLIONFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","MSB.AU","BK4139","MESO","BK7508"],"gpt_icon":0},{"id":"2514132498","title":"BRIEF-Imricor Medical Systems Says Net Loss For Year A$29.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514132498","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514132498?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:15","pubTimestamp":1740618958,"startTime":"0","endTime":"0","summary":"BRIEF-Imricor Medical Systems Says Net Loss For Year A$29.7 MillionFeb 27 (Reuters) - Imricor Medical Systems Inc IMR.AX:NET LOSS FOR YEAR A$29.7 MILLIONFY ADJUSTED NET LOSS A$15.6 MILLIONFurther company coverage: IMR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","IMR.AU","BK7508","BK7007"],"gpt_icon":0},{"id":"2514890782","title":"BRIEF-CSL Says Swissmedic Approves Andembry To Prevent Recurrent Attacks Of Hereditary Angioedema","url":"https://stock-news.laohu8.com/highlight/detail?id=2514890782","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514890782?lang=en_us&edition=fundamental","pubTime":"2025-02-27 08:41","pubTimestamp":1740616874,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Says Swissmedic Approves Andembry To Prevent Recurrent Attacks Of Hereditary AngioedemaFeb 27  - CSL Ltd CSL.AX:SWISSMEDIC APPROVES CSL BEHRING'S ANDEMBRY  FOR PREVENTION OF RECURRENT ATTACKS OF HEREDITARY ANGIOEDEMAFurther company coverage: CSL.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1S3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7508","BK7511","BK7067"],"gpt_icon":0},{"id":"2514894068","title":"Clinuvel Pharmaceuticals Ltd H1 Net Income AUD 14.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514894068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514894068?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:43","pubTimestamp":1740613383,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLXDE4177:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2514489671","title":"Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514489671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514489671?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nTUA8J4MXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2514896706","title":"Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896706","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896706?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609000,"startTime":"0","endTime":"0","summary":"Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter. Financial Results and Operational Update for Half-Year Ended December 31, 2024. NEW YORK, Feb. 26, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024,\"Our FDA approved product Ryoncil will be available in the coming weeks to the children with SR-aGvHD in need of life-saving therapy,\" said Dr. Silviu Itescu, Chief Executive of Mesoblast. \"The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S.\". Ryoncil  U.S. Launch for Steroid-Refractory Acute Graft Versus Host Disease. FDA approved Ryoncil as the first and only therapy for pediat","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","BK7501","BK4139","BK4555","MESO","DDD","ODD","ORR","MSB.AU","CD","BK4585","MSC","03160","BK7508","MMAT","BK4546","R","BK4116","WAC","BK4161","BK4022","BK4575","BK4183","BK4588","BK7067","IBD","BK4099","BK4150","BK4551","BK4604","TM","BK4232","BK4170"],"gpt_icon":1},{"id":"2514896349","title":"Respiri Ltd -  Seeks Trading Halt Pending Announcement Regarding a Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896349?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:18","pubTimestamp":1740608280,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1L2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RSH.AU","BK7007","BK7508","BK7503"],"gpt_icon":0},{"id":"2514339896","title":"Monash IVF Group Ltd -  FY2025 Underlying Group Npat Expected to Be Between a$30.0M and a$31.0M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514339896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514339896?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:13","pubTimestamp":1740608015,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MVF.AU","BK7508","BK7113"],"gpt_icon":0},{"id":"2514950998","title":"Monash IVF Group H1 Adjusted Ebitda AUD 35.592 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514950998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514950998?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:12","pubTimestamp":1740607929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nPLX2490B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MVF.AU","BK7113","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":10,"pageCount":6,"totalSize":147}]}}